Oncology Building a Phase I oncology centre The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.
R&D Sponsored 12 Questions with Matthew Goodman LUCENT Biopharma's Medical Director Matthew Goodman, a doctor by training, specialises in late-phase Clinical Development and Medical Affairs.
Digital Harnessing AI to future-proof biopharma The biopharmaceutical industry has crossed the threshold into the AI era.
R&D Clinical development rates are falling - but it’s not all ba... Over the past decade, a shift has been occurring in biopharma R&D.
R&D Partner Content 2nd ADC Toxicity Summit 2024 Improving Prediction & Translation of ADC Toxicities to Drive More Tolerable ADCs Successfully Into & Through Clinical Development
Digital Digital tools must be used in pharma manufacturing to keep p... The pace of change in drug discovery and clinical development has been unmatched in recent years, with technologies such as AI accelerating these processes.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
